2023-09-012024-08-312024-08-31false11531430A NEW BEGINNING THERAPIES LIMITED2024-11-1386900iso4217:GBPxbrli:pure115314302023-09-01115314302024-08-31115314302023-09-012024-08-31115314302022-09-01115314302023-08-31115314302022-09-012023-08-3111531430bus:SmallEntities2023-09-012024-08-3111531430bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3111531430bus:AbridgedAccounts2023-09-012024-08-3111531430bus:PrivateLimitedCompanyLtd2023-09-012024-08-3111531430core:WithinOneYear2024-08-3111531430core:AfterOneYear2024-08-3111531430core:WithinOneYear2023-08-3111531430core:AfterOneYear2023-08-3111531430core:ShareCapital2024-08-3111531430core:SharePremium2024-08-3111531430core:RevaluationReserve2024-08-3111531430core:OtherReservesSubtotal2024-08-3111531430core:RetainedEarningsAccumulatedLosses2024-08-3111531430core:ShareCapital2023-08-3111531430core:SharePremium2023-08-3111531430core:RevaluationReserve2023-08-3111531430core:OtherReservesSubtotal2023-08-3111531430core:RetainedEarningsAccumulatedLosses2023-08-3111531430core:LandBuildings2024-08-3111531430core:PlantMachinery2024-08-3111531430core:Vehicles2024-08-3111531430core:FurnitureFittings2024-08-3111531430core:OfficeEquipment2024-08-3111531430core:NetGoodwill2024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2024-08-3111531430core:ListedExchangeTraded2024-08-3111531430core:UnlistedNon-exchangeTraded2024-08-3111531430core:LandBuildings2023-08-3111531430core:PlantMachinery2023-08-3111531430core:Vehicles2023-08-3111531430core:FurnitureFittings2023-08-3111531430core:OfficeEquipment2023-08-3111531430core:NetGoodwill2023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-08-3111531430core:ListedExchangeTraded2023-08-3111531430core:UnlistedNon-exchangeTraded2023-08-3111531430core:LandBuildings2023-09-012024-08-3111531430core:PlantMachinery2023-09-012024-08-3111531430core:Vehicles2023-09-012024-08-3111531430core:FurnitureFittings2023-09-012024-08-3111531430core:OfficeEquipment2023-09-012024-08-3111531430core:NetGoodwill2023-09-012024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3111531430core:ListedExchangeTraded2023-09-012024-08-3111531430core:UnlistedNon-exchangeTraded2023-09-012024-08-3111531430core:MoreThanFiveYears2023-09-012024-08-3111531430core:Non-currentFinancialInstruments2024-08-3111531430core:Non-currentFinancialInstruments2023-08-3111531430dpl:CostSales2023-09-012024-08-3111531430dpl:DistributionCosts2023-09-012024-08-3111531430core:LandBuildings2023-09-012024-08-3111531430core:PlantMachinery2023-09-012024-08-3111531430core:Vehicles2023-09-012024-08-3111531430core:FurnitureFittings2023-09-012024-08-3111531430core:OfficeEquipment2023-09-012024-08-3111531430dpl:AdministrativeExpenses2023-09-012024-08-3111531430core:NetGoodwill2023-09-012024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3111531430dpl:GroupUndertakings2023-09-012024-08-3111531430dpl:ParticipatingInterests2023-09-012024-08-3111531430dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3111531430core:ListedExchangeTraded2023-09-012024-08-3111531430dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3111531430core:UnlistedNon-exchangeTraded2023-09-012024-08-3111531430dpl:CostSales2022-09-012023-08-3111531430dpl:DistributionCosts2022-09-012023-08-3111531430core:LandBuildings2022-09-012023-08-3111531430core:PlantMachinery2022-09-012023-08-3111531430core:Vehicles2022-09-012023-08-3111531430core:FurnitureFittings2022-09-012023-08-3111531430core:OfficeEquipment2022-09-012023-08-3111531430dpl:AdministrativeExpenses2022-09-012023-08-3111531430core:NetGoodwill2022-09-012023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3111531430dpl:GroupUndertakings2022-09-012023-08-3111531430dpl:ParticipatingInterests2022-09-012023-08-3111531430dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3111531430core:ListedExchangeTraded2022-09-012023-08-3111531430dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3111531430core:UnlistedNon-exchangeTraded2022-09-012023-08-3111531430core:NetGoodwill2024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2024-08-3111531430core:LandBuildings2024-08-3111531430core:PlantMachinery2024-08-3111531430core:Vehicles2024-08-3111531430core:FurnitureFittings2024-08-3111531430core:OfficeEquipment2024-08-3111531430core:AfterOneYear2024-08-3111531430core:WithinOneYear2024-08-3111531430core:ListedExchangeTraded2024-08-3111531430core:UnlistedNon-exchangeTraded2024-08-3111531430core:ShareCapital2024-08-3111531430core:SharePremium2024-08-3111531430core:RevaluationReserve2024-08-3111531430core:OtherReservesSubtotal2024-08-3111531430core:RetainedEarningsAccumulatedLosses2024-08-3111531430core:NetGoodwill2023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-08-3111531430core:LandBuildings2023-08-3111531430core:PlantMachinery2023-08-3111531430core:Vehicles2023-08-3111531430core:FurnitureFittings2023-08-3111531430core:OfficeEquipment2023-08-3111531430core:AfterOneYear2023-08-3111531430core:WithinOneYear2023-08-3111531430core:ListedExchangeTraded2023-08-3111531430core:UnlistedNon-exchangeTraded2023-08-3111531430core:ShareCapital2023-08-3111531430core:SharePremium2023-08-3111531430core:RevaluationReserve2023-08-3111531430core:OtherReservesSubtotal2023-08-3111531430core:RetainedEarningsAccumulatedLosses2023-08-3111531430core:NetGoodwill2022-09-0111531430core:IntangibleAssetsOtherThanGoodwill2022-09-0111531430core:LandBuildings2022-09-0111531430core:PlantMachinery2022-09-0111531430core:Vehicles2022-09-0111531430core:FurnitureFittings2022-09-0111531430core:OfficeEquipment2022-09-0111531430core:AfterOneYear2022-09-0111531430core:WithinOneYear2022-09-0111531430core:ListedExchangeTraded2022-09-0111531430core:UnlistedNon-exchangeTraded2022-09-0111531430core:ShareCapital2022-09-0111531430core:SharePremium2022-09-0111531430core:RevaluationReserve2022-09-0111531430core:OtherReservesSubtotal2022-09-0111531430core:RetainedEarningsAccumulatedLosses2022-09-0111531430core:AfterOneYear2023-09-012024-08-3111531430core:WithinOneYear2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3111531430bus:Director12023-09-012024-08-3111531430bus:Director22023-09-012024-08-31

A NEW BEGINNING THERAPIES LIMITED

Registered Number
11531430
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

A NEW BEGINNING THERAPIES LIMITED
Company Information
for the year from 1 September 2023 to 31 August 2024

Directors

ADAMS, Scott Nicholas
WEYMES, Amanda Jane

Registered Address

Lindsay House
15-17 Springfield Way
Anlaby
HU10 6RJ

Registered Number

11531430 (England and Wales)
A NEW BEGINNING THERAPIES LIMITED
Statement of Financial Position
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets31,477998
1,477998
Current assets
Debtors4,55,1616,641
Cash at bank and on hand67,07146,081
72,23252,722
Prepayments and accrued income2,0151,023
Creditors amounts falling due within one year6(49,482)(27,910)
Net current assets (liabilities)24,76525,835
Total assets less current liabilities26,24226,833
Creditors amounts falling due after one year(11,363)(20,363)
Net assets14,8796,470
Capital and reserves
Called up share capital22
Profit and loss account14,8776,468
Shareholders' funds14,8796,470
The financial statements were approved and authorised for issue by the Board of Directors on 13 November 2024, and are signed on its behalf by:
ADAMS, Scott Nicholas
Director
WEYMES, Amanda Jane
Director

Registered Company No. 11531430
A NEW BEGINNING THERAPIES LIMITED
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Fixtures and fittings4
2.Average number of employees
The average number of persons employed by the company during the year amounted to

20242023
Average number of employees during the year22
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 September 234,333
Additions728
At 31 August 245,061
Depreciation and impairment
At 01 September 233,335
Charge for year249
At 31 August 243,584
Net book value
At 31 August 241,477
At 31 August 23998
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables5,1606,640
Other debtors11
Total5,1616,641
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
5.Debtors: amounts due after one year
6.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables3,1643,955
Bank borrowings and overdrafts10,5229,661
Taxation and social security15,13910,866
Accrued liabilities and deferred income20,6573,428
Total49,48227,910
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.